FDA Approves Eli Lilly's Groundbreaking Weight-Loss Pill 'Foundayo'

The U.S. Food and Drug Administration (FDA) has given the green light to Eli Lilly's latest weight-loss medication, Foundayo, on Wednesday, potentially reshaping the obesity drug market and challenging Novo Nordisk's existing treatments.

Foundayo, an oral medication taken once daily, specifically targets the appetite-suppressing GLP-1 hormone, offering greater convenience compared to Novo Nordisk's drug, which requires morning administration on an empty stomach. Priced at $149 per month for self-pay customers, Foundayo will be shipped starting April 6, soon extending to pharmacies and telehealth providers.

Analysts project that oral weight-loss drugs like Foundayo could capture up to 20% of the obesity treatment market by 2030, especially among those preferring pills over injections. Recent trials show Foundayo contributing to significant body-weight reduction of up to 15% among patients.